RESUMO
AIMS: To analyze the main contributions to the discovery of the antidiabetic hormone in the period between 1889, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science. METHODS: We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it. The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference. The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions. MAIN RESULTS AND CONCLUSIONS: (1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E. Gley (1900), GL Zülzer (1908) and NC Paulescu (1920). (2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same. (3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic. (4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: "the credit for having produced the pancreatic hormone in a practical available form" (instead of "for the discovery of insulin").
Assuntos
Diabetes Mellitus , Prêmio Nobel , Animais , Cães , História do Século XX , Insulina/uso terapêutico , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/história , Glucagon , Extratos Pancreáticos/uso terapêutico , Hipoglicemiantes/uso terapêuticoRESUMO
The first therapeutic benefits of insulin were recorded after the injection of pancreatic extract, given on January 23, 1922 in Toronto to a 14-year-old teenager. Until then, type I diabetes was always fatal, within weeks or months; the fatal outcome being delayed only at the cost of a drastic low-calorie diet. In previous decades, the importance of the pancreas in the development of diabetes had been pointed out, but all attempts to use a pancreatic extract had failed. It is with the objective of "neutralizing" the destructive effects of pancreatic juice (proteolytic) that the isolation of insulin was carried out by a research team which was totally improbable since it was headed by an orthopedic surgeon, Frederick Banting and a 22-year-old stagiaire, Charles Best. Their work was carried out in the university physiology laboratory of John Macleod and their outcome was made possible thanks to the skills of James Collip who purified the insulin preparation. Scientific reality invites us to emphasize that, Banting works, based on a wrong hypothesis, drew towards an historical discovery. Very quickly recognized as of major importance for medicine, the discovery was greeted by the attribution of the Nobel Prize in 1923. For a hundred years, insulin has not ceased to be an essential drug for tens of millions of patients in the world, but it has been a motor for scientific research: innovation in galenic pharmacy and biopharmacy, in fundamental chemistry as a subject for the study of the structure, analysis and synthesis of proteins, and finally, as a motor for the development of biotechnologies, since insulin was the first drug prepared by DNA-recombinant technology, and marketed in 1982.
Assuntos
Diabetes Mellitus , Insulina , Humanos , História do Século XX , Adolescente , Adulto Jovem , Adulto , Insulina/uso terapêutico , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/história , Prêmio Nobel , Extratos Pancreáticos/uso terapêutico , DNA/uso terapêuticoAssuntos
Suplementos Nutricionais , Enteropeptidase/deficiência , Terapia de Reposição de Enzimas/métodos , Insuficiência Pancreática Exócrina/diagnóstico , Insuficiência Pancreática Exócrina/terapia , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/terapia , Extratos Pancreáticos/uso terapêutico , Humanos , LactenteRESUMO
The dawn of the insulin era can be placed in 1921, when Banting and Best started their experiments which led, a year later, to the successful treatment of diabetes. They were preceded by the discoveries of the pancreatic cause of diabetes by Minkowski and von Mering in 1889 and of the islets by Paul Langerhans in 1869. The achievement of the first targeted treatment in medical history was a landmark of medical progress. However, it was accompanied by a mixture of human greatness and misery. Genius and recklessness, ambition and deception, camaraderie and rivalry, selflessness and pursuit of glory went along with superficial search of the existing literature, poor planning, faulty interpretation of results, failure to reproduce them, and misquoting of reports from other laboratories. Then as now, such faults surface whenever human nature aims to push forward the boundaries of knowledge and pose a real challenge in today's world, as the scientific method strives to keep healthy in the face of growing anti-scientific feelings.
Assuntos
Diabetes Mellitus , Descoberta de Drogas/história , Endocrinologia/história , Insulina , Animais , Pesquisa Biomédica/história , Pesquisa Biomédica/tendências , Glicemia/efeitos dos fármacos , Glicemia/metabolismo , Canadá , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/etiologia , Diabetes Mellitus/história , Diabetes Mellitus/metabolismo , Coma Diabético/sangue , Coma Diabético/tratamento farmacológico , Coma Diabético/história , Cães , Alemanha , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Insulina/metabolismo , Insulina/uso terapêutico , Pâncreas/química , Pâncreas/fisiologia , Extratos Pancreáticos/história , Extratos Pancreáticos/uso terapêutico , Estados UnidosRESUMO
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a complication of pancreaticoduodenectomy (PD). We conducted a randomized clinical trial to determine if high-dose digestive enzymes prevented the development of NAFLD after PD. STUDY DESIGN: This parallel-group, nonblinded, multicenter study enrolled patients undergoing elective PD at Shinshu University School of Medicine, from June 2011 to April 2017. Patients were randomly assigned to receive normal-dose (Excelase: 3.0 g/day [Meiji Seika Pharma Holdings Co, Ltd]) or high-dose digestive enzyme treatment (Excelase: 3.0 g/day; Pancreatin [Tokyo Chemical Industry Co Ltd]: 3.0 g/day; Berizym [Kyowa Pharmaceutical Industry Co Ltd]: 3.0 g/day; and Toughmac-E [Ono Pharmaceutical Co, Ltd]: 3.0 g/day) within 1 week after surgery. Because patients in the control group switched interventions upon receiving a diagnosis of NAFLD, intention-to-treat analysis was used. The primary endpoint was incidence of NAFLD within 1 year, and the secondary endpoints were the incidences of NAFLD at 1, 3, 6, and 12 months and the rate of improvement in NAFLD with high-dose transfer in the control group. The secondary analysis comprised assessment of risk factors for the development of NAFLD. RESULTS: Eighty-four patients were randomly assigned (42 per group), 80 of whom were finally analyzed (39 normal-dose, 41 high-dose). The incidence of NAFLD was significantly lower in the high-dose (8 of 41) compared with the normal-dose (25 of 39) patients (p < 0.001). Multivariate analysis identified normal-dose (odds ratio [OR] 14.65, p < 0.001), total protein ≤ 6.5g/dL (OR 9.01, p = 0.018), pre-albumin ≤ 22.0 mg/dL (OR 7.71, p = 0.018), and pancreatic function diagnostic test ≤ 70% (OR 6.66, p = 0.009) as independent risk factors. There were no adverse effects. The model was accurate (c-index = 0.92) and reliable (Hosmer-Lemeshow test p = 0.32). CONCLUSIONS: High-dose administration of digestive enzymes significantly reduced the onset of NAFLD after PD compared with normal-dose administration. Registration number: UMIN000005595 (http://www.umin.ac.jp/ctr/).
Assuntos
Fármacos Gastrointestinais/uso terapêutico , Hepatopatia Gordurosa não Alcoólica/prevenção & controle , Pancreaticoduodenectomia/efeitos adversos , Idoso , Feminino , Fármacos Gastrointestinais/administração & dosagem , Humanos , Masculino , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Hepatopatia Gordurosa não Alcoólica/etiologia , Extratos Pancreáticos/administração & dosagem , Extratos Pancreáticos/uso terapêutico , Pancreaticoduodenectomia/métodos , Pancreatina/administração & dosagem , Pancreatina/uso terapêutico , Cuidados Pós-Operatórios/métodosRESUMO
INTRODUCTION: The Food and Drug Administration in 2006 required that all pancreatic enzyme products demonstrate bioavailability of lipase, amylase, and protease in the proximal small intestine. METHODS: In this phase I open-label, randomized, crossover trial, 17 adult chronic pancreatitis (CP) patients with severe exocrine pancreatic insufficiency (EPI) underwent two separate gastroduodenal perfusion procedures (Dreiling tube suctioning and [14C]-PEG instillation by an attached Dobhoff tube in the duodenal bulb). Patients received Ensure Plus® alone and Ensure Plus with Zenpep (75,000 USP lipase units) in random order. The bioavailability of Zenpep was estimated by comparing the recovery of lipase, amylase, chymotrypsin activity in two treatment conditions. 14C-PEG was used to correct duodenal aspirates volume. The primary efficacy endpoint was lipase delivery in the duodenum after Zenpep administration under fed conditions. Secondary efficacy endpoints included chymotrypsin and amylase delivery, serum CCK levels, and measuring duodenal and gastric pH. RESULTS: Zenpep administration with a test meal was associated with significant increase in duodenal aspiration of lipase (p = 0.046), chymotrypsin (p = 0.008), and amylase (p = 0.001), compared to the test meal alone, indicating release of enzymes to the duodenum. Lipase delivery was higher in the pH subpopulation (the efficacy population with acid hypersecretors excluded) (p = 0.01). Recovery of [14C]-PEG was 61%. Zenpep was generally well tolerated. All adverse events were mild and transient. CONCLUSIONS: In CP patients with severe EPI, lipase, chymotrypsin and amylase were released rapidly into the duodenum after ingestion of Zenpep plus meal compared to meals alone. Results also reflected the known pH threshold for enzyme release from enteric coated products.
Assuntos
Disponibilidade Biológica , Insuficiência Pancreática Exócrina/tratamento farmacológico , Insuficiência Pancreática Exócrina/metabolismo , Extratos Pancreáticos/farmacocinética , Extratos Pancreáticos/uso terapêutico , Pancreatite Crônica/tratamento farmacológico , Pancreatite Crônica/metabolismo , Adulto , Idoso , Amilases/uso terapêutico , Colecistocinina/metabolismo , Quimotripsina/uso terapêutico , Estudos Cross-Over , Sistemas de Liberação de Medicamentos , Duodeno/metabolismo , Feminino , Humanos , Intestino Delgado/metabolismo , Lipase/uso terapêutico , Masculino , Pessoa de Meia-Idade , Tripsina/uso terapêutico , Adulto JovemRESUMO
BACKGROUND: Historical review on the early development of organotherapy for diabetes [pancreatic extracts (PE)] and its relationship with the social and political circumstances. AREAS OF UNCERTAINTY: The diagnosis of diabetes relied only in the presence of glycosuria and cardinal symptoms. Blood glucose determinations were not regularly available, requiring large volumes for sampling. Micromethods for glycemia were developed just in the last years of the investigated period. Hypoglycemia remains undiscovered. Isolation and purification of PE were difficult tasks due to the unknown chemical structure of the antidiabetic hormone. DATA SOURCES: (1) Berliner Medizinhistoriches Museum der Charité (Humboldt University). (2) GeDenKort Charité-Wissenschaft in Verantwortung. (3) Geheim Staatsarchiv Preußischer Kulturbesitz. (4) Archival Collections, University of Toronto: Thomas Fisher Rare Book Library. Academy of Medicine Collection, F. G. Banting Papers, C. H. Best Papers, J. J. R. Macleod Papers. (5) National Library of Medicine: Pubmed search for the topic of history of insulin. History of Medicine-on syllabus archive. (6) Selected books: The Discovery of Insulin (M. Bliss); Diabetes, Its Medical and Cultural History (D. von Engelhardt); Brown-Séquard (M. J. Aminoff); Diabetes: The Biography (R. Tattersall); The Endocrine Organs (E. Schäfer); The Internal Secretions (E. Gley); Health, race and German politics between national unification and Nazism, 1870-1945 (P. Weindling). THERAPEUTIC ADVANCES: Demonstration that diabetes is a pancreatic disease. The outstanding progress of medical physiology led to the birth of endocrinology and the key concepts of homeostasis. Experimental scientists designed new procedures for complete pancreatectomy and elaboration of PE containing the antidiabetic principle. Organotherapy achieved complete success in the treatment of myxedema and partial success in the treatment of experimental and clinical diabetes. CONCLUSIONS: The organotherapy of diabetes was an obliged step to facilitate the identification of the antidiabetic hormone. Organotherapy of diabetes was a paradigm for the integration of basic and applied knowledge about hormone action and development of endocrine pharmacology.
Assuntos
Diabetes Mellitus/história , Hipoglicemiantes/história , Extratos Pancreáticos/história , Glicemia , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/tratamento farmacológico , Endocrinologia/história , História do Século XIX , História do Século XX , Humanos , Hipoglicemiantes/uso terapêutico , Pâncreas/fisiopatologia , Extratos Pancreáticos/uso terapêuticoRESUMO
BACKGROUND: Patients with cystic fibrosis have to take enzymatic supplements to allow for food digestion. However, an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy (PERT) is inexistent, and lipid content of meals is used as a rough criterion. OBJECTIVE: In this study, an in vitro digestion model was set up to determine the theoretical optimal dose (TOD) of enzymatic supplement for a selection of foods, which is the dose that allows for maximum lipolysis extent. METHODS: A static in vitro digestion model was applied to simulate digestion of eight foods covering a wide range of lipid contents. First, the dose of the enzymatic supplement was fixed at 2000 lipase units per gram of fat (LU/g fat) using intestinal pH and bile salt concentration as variables. Second, intestinal pH and bile salt concentrations were fixed and the variable was the dose of the enzymatic supplement. Lipolysis extent was determined by measuring the free fatty acids released from initial triglycerides content of foods after digestion. Results in terms of percentage of lipolysis extent were fitted into a linear-mixed segmented model and the deducted equations were used to predict the TOD to reach 90% of lipolysis in every food. In addition, the effect of intestinal pH and bile salt concentration were investigated. RESULTS: The predictive equations obtained for the assessed foods showed that lipolysis was not only dependent on the dose of the enzyme supplement or the lipid content. Moreover, intestinal pH and bile salt concentration had significant effects on lipolysis. Therefore an evidence-based model can be developed taking into account these variables. CONCLUSIONS: Depending on food characteristics, a specific TOD should be assigned to achieve an optimal digestion extent. This work represents a first step towards an evidence-based method for PERT dosing, which will be applied in an in vivo setting to validate its efficacy.
Assuntos
Fibrose Cística/tratamento farmacológico , Terapia de Reposição de Enzimas/métodos , Simulação por Computador , Fibrose Cística/metabolismo , Digestão/efeitos dos fármacos , Medicina Baseada em Evidências , Análise de Alimentos , Fármacos Gastrointestinais/uso terapêutico , Humanos , Técnicas In Vitro , Lipase/uso terapêutico , Lipólise/efeitos dos fármacos , Modelos Biológicos , Pâncreas/enzimologia , Extratos Pancreáticos/uso terapêutico , Peptídeo Hidrolases/uso terapêuticoRESUMO
Dorsal pancreatic agenesis is an extremely rare entity characterised by absence of body and tail of pancreas, while there are so many other developmental anomalies of the pancreas that have been reported. Here we report a 25-year-old young man who presented with pain in the abdomen, recurrent loose stools and hyperglycaemia. On radiological imaging study, there was complete agenesis of the dorsal pancreas except for thin stripe of tissue at the level of the uncinate process. Both exocrinedysfunction and endocrine dysfunction were present in this patient. Patient was supplemented with pancreatic enzyme preparation and insulin.
Assuntos
Anormalidades Congênitas/diagnóstico por imagem , Anormalidades Congênitas/tratamento farmacológico , Insulina/uso terapêutico , Pâncreas/anormalidades , Extratos Pancreáticos/uso terapêutico , Adulto , Colangiopancreatografia por Ressonância Magnética , Anormalidades Congênitas/patologia , Diabetes Mellitus Tipo 1/etiologia , Diagnóstico Diferencial , Humanos , Masculino , Pâncreas/diagnóstico por imagem , Pâncreas/patologia , Doenças Raras/complicações , Doenças Raras/diagnóstico por imagem , Tomografia Computadorizada por Raios XRESUMO
OBJECTIVE: To evaluate the effects of pancreatic enzyme substitution (PES) in selected very low birthweight (VLBW) infants with poor postnatal growth despite intensified nutritional support. DESIGN: Retrospective historic cohort study with matched controls. SETTING: Single level III neonatal intensive care unit. PATIENTS: Infants with a gestational age at birth <32 weeks and birth weight <1500 g born between 1 January 2005 and 31 December 2014 (n=26) who received PES for restricted postnatal growth despite intensified enteral nutritional support in comparison with infants matched for birth weight, birth year, gestational and postnatal age (n=52). INTERVENTIONS: PES 15-93 mg/g fat with enteral feeds. MAIN OUTCOME MEASURES: The difference in SD score (SDS) differences for weight during the 7 days before and after onset of PES and weight gain in g/kg/d. Data are presented as median (P10-P90). RESULTS: Gestational age was 26.6 (24.4-29.9) weeks in enzyme substituted versus 26.4 (24.7-29.9) weeks in matched controls, and birth weight was 648(420-950)g versus 685(453-949)g. SDS differences for weight improved after onset of PES by 0.18(-0.12 to 0.53) in PES infants versus -0.04(-0.31 to 0.44) in controls. Weight gain increased in the PES group from 13.6 (4.2-22.9) g/kg/day in the week before to 19.0 (10.9-29.1) g/kg/day in the week after the onset of PES. There was no difference in weight gain in substituted subgroups receiving formula/pasteurised human milk versus unpasteurised human breast milk or who had pancreatic-specific elastase-1 concentrations in stool >200 µg/g versus≤200 µg/g. No adverse effects were noted. CONCLUSIONS: PES in selected VLBW infants with growth failure despite intensified enteral nutritional support was associated with a significant increase in weight gain in the first 7 days of PES.k.
Assuntos
Terapia de Reposição de Enzimas/métodos , Extratos Pancreáticos/uso terapêutico , Manutenção do Peso Corporal/fisiologia , Estudos de Casos e Controles , Estudos de Coortes , Nutrição Enteral/métodos , Feminino , Alemanha , Transtornos do Crescimento/diagnóstico , Transtornos do Crescimento/fisiopatologia , Transtornos do Crescimento/terapia , Humanos , Lactente , Recém-Nascido , Recém-Nascido Prematuro/crescimento & desenvolvimento , Recém-Nascido de muito Baixo Peso/crescimento & desenvolvimento , Masculino , Apoio Nutricional/métodos , Resultado do Tratamento , Aumento de Peso/fisiologiaRESUMO
PURPOSE: Survival with advanced pancreatic cancer is less than 12 months. Pancreatic exocrine insufficiency may contribute to pancreatic cancer-related cachexia, via nutrient malabsorption. We aimed to determine the feasibility of prescribing pancreatic extract (Creon®) for patients with advanced pancreatic cancer. METHODS: Patients with advanced pancreatic cancer, without frank malabsorption, were randomised in this feasibility study to pancreatic extract 50,000 units with meals and 25,000 units with snacks, or placebo. Standardised dietary advice was given. Anti-cancer and supportive care treatments were permitted. Outcomes included weight, body mass index (BMI), quality of life (QLQC30, PAN26), survival and nutritional assessment (PG-SGA). RESULTS: Eighteen patients were randomised before study closure due to slow recruitment. Baseline characteristics were well matched. Weight loss prior to randomisation was numerically greater in the pancreatic extract group (mean 0.7 vs 2.2 kg). Weight loss was numerically greater in the placebo group, however not significantly. No differences in BMI or nutrition score were seen. Quality of life did not differ between study groups. Median overall survival was 17 (95% CI 8.1-48.7) weeks in the control group, and 67.6 (95% CI 14.1-98.4) weeks in the pancreatic extract group (p = 0.1063). Only 17% (18/106) of potentially eligible patients were recruited, related to patient/family reluctance, rapid clinical deterioration and patients already prescribed pancreatic extract. A moderate pill burden was noted. CONCLUSION: Despite intriguing survival results, this study was not sufficiently feasible to proceed to a fully powered comparative study. A multi-centre study would be required to exclude a significant difference in outcomes.
Assuntos
Caquexia/etiologia , Insuficiência Pancreática Exócrina/terapia , Extratos Pancreáticos/uso terapêutico , Neoplasias Pancreáticas/terapia , Qualidade de Vida/psicologia , Idoso , Método Duplo-Cego , Estudos de Viabilidade , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/mortalidade , Projetos Piloto , Taxa de Sobrevida , Resultado do TratamentoRESUMO
The exocrine pancreatic insufficiency affects more than 80% of cystic fibrosis (CF) infants. Pancreatic insufficiency is diagnosed by low levels of fecal elastase. An optimal caloric intake, a pancreatic enzyme treatment are the keys to maintain a good nutritional status. The fat soluble vitamins supplementation will be associated with pancreatic enzymes treatment and will be adapted to plasma levels. Iron and oligo-element deficiency such as zinc is common. The pancreatic enzymes function is not optimal in the proximal bowel: the intraluminal intestinal pH is low because of the absence of bicarbonate release by the pancreas. The use of proton pump inhibitors may improve the functionality of pancreatic enzymes treatment. New therapies such as ivacaftor in patients with a G551D mutation allows a weight gain in particular by restoring intestinal pH similar to controls. Lengthening of the life expectancy of patients with CF is accompanied by the emergence new aspects of the disease, especially diabetes, favored by pancreatic cystic fibrosis resulting in an anatomical destruction of pancreatic islets. Currently, diabetes affects a third of the patients after 20 years, and half after 30 years. Cystic fibrosis-related diabetes is a major factor of morbidity-mortality in all stages of the disease and is characterized by a preclinical phase of glucose intolerance particularly long reaching up to 10 years. Its pathophysiology combines a lack of insulin secretion, an insulin resistance secondary to chronic infection, and a decrease in the production of the GIP and GLP-1. The insulin secretion depending on the channel chlorine (Cystic Fibrosis Transmembrane conductance Regulator [CFTR]) activity at the membrane surface of insulin cell is reduced prior to the occurrence of pancreatic histological lesions. At the stage of diabetes, obtaining a normoglycemia by insulin treatment began very early allows to slow the decline of lung function and nutritional status. Given the silent phase of diabetes, screening it is recommended by the realization of an annual OGTT from 10 years of age, or before in severe forms of CF. New treatments of CF able to target CFTR showed their efficacy in slowing the decline of lung function, and could also contribute to slow or prevent the onset of diabetes.
Assuntos
Fibrose Cística/diagnóstico , Fibrose Cística/fisiopatologia , Diabetes Mellitus/diagnóstico , Diabetes Mellitus/fisiopatologia , Insuficiência Pancreática Exócrina/diagnóstico , Insuficiência Pancreática Exócrina/fisiopatologia , Ilhotas Pancreáticas/fisiopatologia , Pâncreas Exócrino/fisiopatologia , Adolescente , Adulto , Criança , Pré-Escolar , Fibrose Cística/terapia , Diabetes Mellitus/terapia , Ingestão de Energia/fisiologia , Insuficiência Pancreática Exócrina/terapia , Teste de Tolerância a Glucose , Humanos , Lactente , Expectativa de Vida , Extratos Pancreáticos/uso terapêutico , Inibidores da Bomba de Prótons/uso terapêutico , Adulto JovemRESUMO
A 78 year old patient with type 2 diabetes mellitus was hospitalized because of weakness and poor nutritional status. For several years, he suffered from an unintended weight loss and chronic, pulpy diarrhea. On examination, we found a severe loss of muscle and fat tissue as well as difficulty swallowing. An adequate nutritional therapy with combined parenteral and enteral nutrition was implemented under regular monitoring of electrolytes and volume status, under which the state of health improved noticeably, while steatorrhea improved under substitution of pancreatic enzymes.
Assuntos
Caquexia/etiologia , Diabetes Mellitus Tipo 2/diagnóstico , Insuficiência Pancreática Exócrina/diagnóstico , Metabolismo , Desnutrição Proteico-Calórica/etiologia , Redução de Peso , Idoso , Caquexia/terapia , Terapia Combinada , Comorbidade , Diabetes Mellitus Tipo 2/terapia , Diagnóstico Diferencial , Nutrição Enteral , Insuficiência Pancreática Exócrina/terapia , Humanos , Masculino , Extratos Pancreáticos/uso terapêutico , Nutrição Parenteral Total , Desnutrição Proteico-Calórica/terapiaAssuntos
Doenças do Colo/induzido quimicamente , Doenças do Colo/patologia , Extratos Pancreáticos/efeitos adversos , Pancreatina/efeitos adversos , Fibrose Cística/tratamento farmacológico , Fibrose/induzido quimicamente , Fibrose/patologia , Humanos , Extratos Pancreáticos/uso terapêutico , Pancreatina/uso terapêutico , Pancrelipase/efeitos adversos , Pancrelipase/uso terapêutico , Ácidos Polimetacrílicos/efeitos adversos , Ácidos Polimetacrílicos/uso terapêutico , Medição de Risco , Reino UnidoRESUMO
INTRODUCTION: Short bowel syndrome (SBS) is an increasingly common condition encountered across neonatal intensive care units. Improvements in parenteral nutrition (PN), neonatal intensive care and surgical techniques, in addition to an improved understanding of SBS pathophysiology, have contributed in equal parts to the survival of this fragile subset of infants. Prevention of intestinal failure associated liver disease (IFALD) and promotion of intestinal adaptation are primary goals of all involved in the care of these patients. While enteral nutritional and pharmacological strategies are necessary to achieve these goals, there remains great variability in the application of therapeutic strategies in units that are not necessarily evidence-based. MATERIALS AND METHODS: A search of major English language medical databases (SCOPUS, Index Medicus, Medline, and the Cochrane database) was conducted for the key words short bowel syndrome, medical management, nutritional management and intestinal adaptation. All pharmacological and nutritional agents encountered in the literature search were classified based on their effects on absorptive capacity, intestinal adaptation and bowel motility that are the three major strategies employed in the management of SBS. The Oxford Center for Evidence-Based Medicine (CEBM) classification for levels of evidence was used to develop grades of clinical recommendation for each variable studied. RESULTS: We reviewed various medications used and nutritional strategies included soluble fiber, enteral fat, glutamine, probiotics and sodium supplementation. Most interventions have scientific rationale but little evidence to support their role in the management of infant SBS. While some of these agents symptomatically improve diarrhea, they can adversely influence pancreatico-biliary function or actually impair intestinal adaptation. Surgical anatomy and liver function are two important variables that should determine the selection of pharmacological and nutritional interventions. DISCUSSION: There is a paucity of research investigating optimal clinical practice in infant SBS and the little evidence available is consistently of lower quality, resulting in a wide variation of clinical practices among NICUs. Prospective trials should be encouraged to bridge the evidence gap between research and clinical practice to promote further progress in the field.
Assuntos
Nutrição Enteral/métodos , Síndrome do Intestino Curto/terapia , Atrofia , Estudos de Casos e Controles , Estudos de Coortes , Terapia Combinada , Cuidados Críticos/métodos , Diarreia Infantil/etiologia , Diarreia Infantil/prevenção & controle , Gorduras na Dieta/administração & dosagem , Gorduras na Dieta/efeitos adversos , Gorduras na Dieta/uso terapêutico , Fibras na Dieta/uso terapêutico , Medicina Baseada em Evidências , Insuficiência Pancreática Exócrina/etiologia , Insuficiência Pancreática Exócrina/prevenção & controle , Alimentos Formulados , Fármacos Gastrointestinais/farmacologia , Fármacos Gastrointestinais/uso terapêutico , Hormônios Gastrointestinais/metabolismo , Motilidade Gastrointestinal/efeitos dos fármacos , Glutamina/uso terapêutico , Humanos , Lactente , Alimentos Infantis , Recém-Nascido , Unidades de Terapia Intensiva Neonatal , Hepatopatias/etiologia , Hepatopatias/prevenção & controle , Pâncreas Exócrino/metabolismo , Pâncreas Exócrino/patologia , Extratos Pancreáticos/uso terapêutico , Nutrição Parenteral/efeitos adversos , Peptídeos/uso terapêutico , Probióticos/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto , Síndrome do Intestino Curto/complicações , Síndrome do Intestino Curto/fisiopatologia , Síndrome do Intestino Curto/reabilitaçãoAssuntos
Dor Crônica/etiologia , Desnutrição/etiologia , Pseudocisto Pancreático/etiologia , Pancreatite Crônica/complicações , Pancreatite Crônica/terapia , Dor Crônica/terapia , Fidelidade a Diretrizes , Humanos , Desnutrição/terapia , Pancreatectomia , Extratos Pancreáticos/uso terapêutico , Pseudocisto Pancreático/terapiaRESUMO
Canine exocrine pancreatic insufficiency (EPI) is an alimentary tract disorder causing malabsorption and debilitations in affected individuals. This article covers predisposing factors to EPI and response to therapy. Although relatively easy to diagnose, knowledge of breed predispositions (and also of those breeds where the disease is less common) can guide the clinician. Numerous studies have examined therapy for EPI, and a key finding is the variability in response among affected dogs. This implies that close monitoring and individual tailoring of therapy is needed to maximize the chance of success. Important factors affecting outcome are the choice of enzyme preparation, presence of hypocobalaminemia, and the response to the first 2 to 3 months of therapy.